Rapid and Effective Elimination of Myoglobin with CytoSorb® Hemoadsorber in Patients with Severe Rhabdomyolysis

被引:8
|
作者
Albrecht, Frederic [1 ,2 ]
Schunk, Stefan [2 ,3 ]
Fuchs, Maren [1 ,2 ]
Volk, Thomas [1 ,2 ]
Geisel, Juergen [2 ,4 ]
Fliser, Danilo [2 ,3 ]
Meiser, Andreas [1 ,2 ]
机构
[1] Saarland Univ, Med Ctr, Dept Anesthesiol Intens Care & Pain Therapy, Homburg, Germany
[2] Saarland Univ, Fac Med, Homburg, Germany
[3] Saarland Univ, Med Ctr, Dept Internal Med Nephrol & Hypertens 4, Homburg, Germany
[4] Saarland Univ, Med Ctr, Dept Clin Chem & Lab Med, Homburg, Germany
关键词
Acute kidney injury; Continuous renal replacement therapy; Hemoadsorber; Myoglobin; Renal replacement therapy; Rhabdomyolysis; HEMODIAFILTRATION; REMOVAL;
D O I
10.1159/000534479
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Rhabdomyolysis is characterized by destruction of muscle fibers by various causes and is diagnosed by increased creatine kinase concentrations in the blood. Myoglobin released into the blood may cause acute kidney injury. In this randomized controlled study, we hypothesized that myoglobin elimination would be faster when a hemoadsorber was added to a continuous veno-venous hemodialysis (CVVHD). Methods: Four patients in the control group received CVVHD with a high cut-off hemofilter using high blood and dialysate flows for 48 h. Four patients in the CytoSorb group received the same treatment, but in addition, the hemoadsorber CytoSorb (R) was inserted in front of the hemofilter and replaced once after 24 h. Blood samples were drawn simultaneously before (pre) and after (post) the hemofilter or else the hemoadsorber, after 5 and 30 min, as well as after 2, 4, 8, and 24 h. All measurements were repeated the next day after the hemoadsorber had been renewed in the CytoSorb group. Primary outcome was the area under the curve (AUC) of the relative myoglobin concentrations as percent of baseline. To evaluate the efficacy of myoglobin removal, relative reductions in myoglobin concentrations during one passage through each device at each time point were calculated. Results: Patients in the CytoSorb group had a significantly lower AUC during the first 24 h (42 +/- 10% vs. 63 +/- 6%, p = 0.029) as well as during the observation period of 48 h (26 +/- 7% vs. 51 +/- 12%, p = 0.029). The relative reductions for myoglobin were considerably higher in the CytoSorb group compared to the control group during the first 8 h. Conclusion: Myoglobin concentrations declined considerably faster when CytoSorb was added to a CVVHD. When compared to a high-cut-off hemofilter, efficacy of CytoSorb in myoglobin elimination was much better. Because of saturation after 8-12 h an exchange may be necessary.(c) 2023 The Author(s).Published by S. Karger AG, Basel
引用
收藏
页码:88 / 95
页数:8
相关论文
共 45 条
  • [41] Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?
    Bastida, Carla
    Antonia Also, Maria
    Manuel Pericas, Juan
    Letang, Emili
    Tuset, Montse
    Maria Miro, Josep
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2014, 32 (09): : 579 - 582
  • [42] Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment
    Joao, Cristina
    Freitas, Jose
    Gomes, Fernando
    Geraldes, Catarina
    Coelho, Ines
    Neves, Manuel
    Lucio, Paulo
    Esteves, Susana
    Esteves, Graca V.
    ANNALS OF HEMATOLOGY, 2016, 95 (06) : 931 - 936
  • [43] Extracorporeal decarboxylation in patients with severe traumatic brain injury and ARDS enables effective control of intracranial pressure
    Munoz-Bendix, Christopher
    Beseoglu, Kerim
    Kram, Rainer
    CRITICAL CARE, 2015, 19
  • [44] Continuous Renal Replacement Therapy With oXiris Filter May Not be an Effective Resolution to Alleviate Cytokine Release Syndrome in Non-AKI Patients With Severe and Critical COVID-19
    Kang, Kai
    Luo, Yunpeng
    Gao, Yang
    Zhang, Jiannan
    Wang, Changsong
    Fei, Dongsheng
    Yang, Wei
    Meng, Xianglin
    Ye, Ming
    Gao, Yan
    Liu, Haitao
    Du, Xue
    Ji, Yuanyuan
    Wei, Jieling
    Xie, Wanqiu
    Wang, Jun
    Zhao, Mingyan
    Yu, Kaijiang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
    Zannetti, Beatrice Anna
    Zamagni, Elena
    Santostefano, Marisa
    De Sanctis, Lucia Barbara
    Tacchetti, Paola
    Mancini, Elena
    Pantani, Lucia
    Brioli, Annamaria
    Rizzo, Raffaella
    Mancuso, Katia
    Rocchi, Serena
    Pezzi, Annalisa
    Borsi, Enrica
    Terragna, Carolina
    Marzocchi, Giulia
    Santoro, Antonio
    Cavo, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) : 647 - 652